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Disruption of Doppel prevents neurodegeneration in mice with
extensive Prnp deletions
Abstract
The Prnp gene encodes the cellular prion protein PrP(C). Removal of its ORF does not result in
pathological phenotypes, but deletions extending into the upstream intron result in cerebellar
degeneration, possibly because of ectopic cis-activation of the Prnd locus that encodes the PrP(C)
homologue Doppel (Dpl). To test this hypothesis, we removed Prnd from Prnp(o/o) mice by transallelic
meiotic recombination. Balanced loxP-mediated ablation yielded mice lacking both PrP(C) and Dpl
(Prn(o/o)), which developed normally and showed unimpaired immune functions but suffered from male
infertility. However, removal of the Prnd locus abolished cerebellar degeneration, proving that this
phenotype is caused by Dpl upregulation. The absence of compound pathological phenotypes in
Prn(o/o) mice suggests the existence of alternative compensatory mechanisms. Alternatively, Dpl and
PrP(C) may exert distinct functions despite having partly overlapping expression profiles.
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The Prnp gene encodes the cellular prion protein PrPC. Removal of
its ORF does not result in pathological phenotypes, but deletions
extending into the upstream intron result in cerebellar degenera-
tion, possibly because of ectopic cis-activation of the Prnd locus
that encodes the PrPC homologue Doppel (Dpl). To test this hy-
pothesis, we removed Prnd from Prnpo/o mice by transallelic
meiotic recombination. Balanced loxP-mediated ablation yielded
mice lacking both PrPC and Dpl (Prno/o), which developed normally
and showed unimpaired immune functions but suffered from male
infertility. However, removal of the Prnd locus abolished cerebellar
degeneration, proving that this phenotype is caused by Dpl up-
regulation. The absence of compound pathological phenotypes in
Prno/o mice suggests the existence of alternative compensatory
mechanisms. Alternatively, Dpl and PrPC may exert distinct func-
tions despite having partly overlapping expression profiles.
prion protein  Dpl  cerebellar degeneration  transallelic
meiotic recombination
Transmissible spongiform encephalopathies are fatal neuro-degenerative disorders (1). The only identified protein com-
ponent of the infectious agent, or prion, is PrPSc, a modified form
of the cellular prion protein PrPC. Conversion of PrPC to PrPSc
is a central pathogenetic event (1); mice lacking PrPC are
resistant to prion inoculation (2) and do not replicate prions (3).
Prnd encodes a 179-residue protein, termed Doppel (Dpl) (4),
that shows 25% identity with the C-proximal domain of PrPC
but lacks the octapeptide repeats and hydrophobic region of
PrPC. Both PrPC and Dpl are glycosyl phosphatidyl inositol-
anchored membrane proteins (5, 6). The structures of Dpl and
PrPC are strikingly similar (4). Prnd is transcribed strongly in
testis and heart, moderately in spleen and some other organs,
and transiently in developing brain, but very weakly in adult
brain (7). In contrast, Prnp is highly expressed in neurons (8).
Ablation of Prnd showed that Dpl is dispensable for prion
pathogenesis (9). Although Prndneo/neo mice develop normally,
males are infertile; Dpl-deficient sperms are unable to fertilize in
vitro unless the zona pellucida of the ovum is partially dissected (10).
Ataxia and cerebellar Purkinje cell (PC) loss were described
in Prnp-ablated Ngsk (11), Rcm0 (5), and Zu¨rich II (ZH-II) (12)
mice that overexpress Dpl but not in ZH-I (2) and Edbr (13) mice
with unadulterated Dpl expression. Removal of the Prnp splice
acceptor may provoke neurodegeneration by yielding transcrip-
tional control of Prnd to the Prnp promoter and, hence, inap-
propriately up-regulating Dpl in brain (14, 15).
Dpl overexpression in brains of PrP-deficient mice supports
the notion that ectopic Dpl, rather than loss of PrPC, causes
neuronal degeneration in ataxic Prnp-deficient mice (16); onset
of ataxia inversely correlates with Prnd transcription (12).
Dpl-overexpressing mice were rescued from neuronal degener-
ation by introduction of a Prnp transgene; hence, absence of
PrPC is necessary for Dpl to induce cell death.
To establish the role of Dpl in the neurodegenerative pheno-
type of mice with extensive Prnp deletions, we disrupted Prnd in
the ataxic ZH-II mice by using transallelic targeted meiotic
recombination (TAMERE) (17). Offspring carrying the double
deletion exhibited no abnormalities, except for male sterility, and
they did not develop ataxia, proving the causal role of Dpl
overexpression in ZH-II mice. Dpl does not appear to compen-
sate for the loss of any unrecognized function of PrP, as has been
suggested (4, 18).
Materials and Methods
Meiotic Recombination. Genomic rearrangements within the Prn
(Prnp and Prnd) locus were produced in vivo by TAMERE (17).
ZH-II mice homozygous for a Prnp allele whose exon 3 was
replaced by a loxP site (12) were crossed with hemizygous
synaptonemal complex protein 1 (Sycp1)-Cre mice (19). The
progeny were crossed with animals homozygous for a Prnd allele
containing a neomycin resistance cassette flanked by two loxP
sites (10) to generate ‘‘transloxer’’ male mice whose meiotic cells
may undergo targeted recombination. Reciprocal chromosomal
translocations gave rise to deletion of the locus comprised within
the loxP sites. Transloxer males were mated with wild-type
females, and PCR with tail DNA was used to screen the progeny.
The breakpoint was sequenced with the same primers as used for
PCR: D, 5-TGCAGGTGACTTTCTGCATTCTGG-3; and E,
5-TGAGTCTTGGAGGGATCAGGAGG.
Western Blot and Northern Blot Analyses. Brain homogenates (20%,
wtvol) were prepared as described (20). Samples (50 g for PrP
and 100 g for Dpl) were electrophoresed through 12% SDS
PAGE gels and processed as described (20). PrP was detected
with mAb ICSM18 (21); Dpl was probed with polyclonal anti-
Dpl rabbit antiserum (12). For Northern blotting, 20 g of total
RNA was processed as described (10) with probes labeled with
[-32P] dCTP by random priming. Probes were sequenced as
follows: A (PrP exons 1–2), ATCAGCAGACCGATTCTGGG-
CGCTGCGTCGCATCGGTGGCAGGACTCCTGAGTATA-
TTTCAGAACTGAACCATTTCAACCGAGCTGAAGCAT-




C contains the entire Dpl ORF.
Viral Infection. Mice were infected i.v. with 2  106 plaque-
forming units (pfu) of vesicular stomatitis virus (VSV)-Indiana
and serum was collected at the time points indicated. Serial
2-fold dilutions of 40-fold prediluted sera were preincubated
Abbreviations: Dpl, Doppel; PC, Purkinje cell; ZH-III, Zu¨rich I and II; TAMERE, targeted
meiotic recombination; pfu, plaque-forming units; VSV, vesicular stomatitis virus; LCMV,
lymphocytic choriomeningitis virus; Sycp1, synaptonemal complex protein 1; FACS, fluo-
rescence-activated cell sorting; PE, phycoerythrin.
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with an equal volume of medium containing 500 pfuml VSV for
90 min, and the remaining nonneutralized infectivity was de-
tected on Vero cell monolayers. The highest serum dilution that
reduced infectivity of virus by 50% was counted as the neutral-
izing Ab titer. Lymphocytic choriomeningitis virus (LCMV)-
specific cytotoxic T lymphocytes were detected in blood by using
gp33–41:H2Db-tetramers on day 13 after infection with 200 pfu
of LCMV.WE. LCMV-specific IgG Abs were measured against
recombinant LCMV nucleoprotein in an ELISA.
Histopathology. Brains were fixed in 4% paraformaldehyde, par-
affin-embedded, and cut into 2-m sections. Sections were
stained with hematoxylineosin and for glial fibrillary acidic
protein, as described (12).
Fluorescence-Activated Cell Sorting (FACS) Analysis. Two- and three-
color FACS analyses were performed on a FACSCalibur cy-
tometer (Becton Dickinson) as described (22). The following
anti-mouse Abs were used (Pharmingen): peridinin-chlorophyll-
a-protein (PerCP)-labeled anti-B220; FITC-labeled anti-CD21;
phycoerythrin (PE)-labeled anti-CD23 and anti-CD8; FITC-
labeled anti-CD4 and anti-AA4.1; PE-labeled anti-Ter119 and
anti-CD11b; and FITC-labeled anti-Thy1.2.
Results
Generation of Prno/o Mutant Mice. The minimal SycP1 promoter
(19) drives expression of Cre during the zygotene stage of
meiotic prophase I. We performed sequential crosses of SycP1-
Cre mice with ZH-II mice, whose Prnp gene is replaced by a
single loxP site (Prnplox1) (12), and Prndneo/neo mice, carrying a
neomycin-resistance cassette flanked by loxP sites in place of the
Prnd coding exon (Prndneo) (10). This breeding scheme juxta-
poses loxP sites encircling the Prnp and Prnd loci (Fig. 1A) during
homologous chromosome pairing in the first meiotic division.
Offspring were screened for the occurrence of a fused allele
lacking both Prnp and Prnd (Prno).
After transallelic meiotic recombination, we expected two
novel alleles to segregate in haploid germ cells: one allele
containing a duplication of the intergenic sequence and another
allele lacking 16 kb encompassing Prnp and Prnd (Fig. 1 A).
PCR primers D and E were designed to yield a 600-bp product
after transallelic meiotic recombination; their annealing sites are
separated by18 kb in the wild-type locus. Genomic testis DNA
from transloxing males was consistently positive for the fusion
chromosome-specific PCR product (Fig. 1B). This band was not
observed in control somatic liver DNA nor in testes lacking the
SycP1-Cre transgene (Fig. 1B). Hence, transallelic recombina-
tion occurred in germ cells, but not in somatic cells, of trans-
loxing males.
To obtain mice carrying fusion chromosomes with a deletion
of the Prn locus, we mated transloxing males with wild-type
females. We found that 1 of 482 pups (0.2%) carried the
recombined allele, as judged by the appearance of the diagnostic
600-bp PCR product. Offspring were not screened for the
duplicated allele. Sequencing of the floxed allele confirmed the
absence of the Prnp and Prnd loci (data not shown).
Fig. 1. Recombination strategy. (A) Schematic representation of Cre-mediated TAMERE. In ZH-II mice, 0.26 kb of intron 2, the entire PrP ORF, and the 3
noncoding region of exon 3 were replaced by a 34-bp loxP sequence. In Prndneo/neo mice, the Dpl ORF was replaced by a selection cassette flanked by loxP
sequences. These lines were intercrossed to produce triple transgenic ‘‘transloxing’’ males containing the Prnplox1, Prndneo, and SycP1-Cre alleles (Fig. 1A). After
chromosome pairing and Cre expression in meiotic prophase, transallelic recombination generates two novel alleles. In the first allele (Prno), the intergenic
sequence is deleted. In the second allele (Prndup), the intergenic sequence between Prnp and Prnd is produced in the same orientation as in the original Prndup.
Boxes in A–C show DNA probes used for Northern blot analysis. (B) PCR amplification of genomic DNA from testes of transloxing males, with or without the
SycP1-Cre transgene. Primers D and E amplify a 0.6-kb fragment diagnostic of the deleted locus only in presence of Cre. No recombination was found in somatic
transloxer tissues. (C) Northern blot analysis confirmed the absence of any transcripts in the Prno/o mice with probe B and C in different tissues, but a weak band
was detected with probe A. Dup, duplication; Tes, testis; Som, somatic; B, brain; S, spleen; T, testis.











Because the loss of Dpl affects male fertility, and because Cre
may be genotoxic, we investigated whether the loss of both PrP
and Dpl would affect spermatozoa. However, transmission of the
Prnplox1, Prndneo, and SycP1-Cre alleles occurred in an undis-
torted Mendelian ratio, and sperms from transloxing males did
not show any obvious abnormalities (data not shown).
We then performed detailed transcriptional analyses of var-
ious PrP and Dpl-related mutant mice (Fig. 1C). By using a
100-bp probe specific for Prnp exons 1 and 2 (probe A), a
low-intensity 1.5-kb transcript was detectable in Prno/o brains,
which may arise from intergenic splicing including Prnd exons 2b
and 3, which were not removed by gene targeting. A larger Prnp
transcript was present also in ZH-I brains, possibly resulting
from a fused mRNA containing the cassette inserted into Prnp
exon 3 (23). None of these transcripts were detected with a probe
containing 100 bp of the Prnp ORF (probe B). No hybridization
was detected in Prno/o and Prndo/o mice with a probe containing
the Dpl ORF (probe C), but Dpl transcripts were slightly larger
in ZH-I and Ngsk (11) than in wild-type testes. RT-PCR
confirmed the absence of Prnp and Prnd mRNAs in homozygous
mice (data not shown).
Male Prno/o Mice Develop Normally but Are Infertile. Male mice
lacking Dpl are infertile (10). PrPC is also highly expressed in
testis and is processed in mature sperms into a nonanchored
C-terminally truncated peptide (24). However, Prnpo/o mice are
fertile (23). Female Prno/o mice were fertile and yielded litter
sizes similar to those of wild-type mice, whereas breeding of
Prno/o males (n  5) for 5 months did not yield any litters.
Prn/ and Prn/o male littermates yielded multiple litters.
Histological analysis of various organs did not show gross
abnormalities. Prno/o mice did not show any neurodevelopmental
defects, yet their sperms had malformations similar to those of
Dpl-deficient sperms (data not shown). Therefore, removal of
PrP from Dpl-deficient mice did not induce any additional
abnormalities and failed to accentuate the sperm phenotype.
Hence, the absence of major defects in mice lacking PrPC is
unlikely to result from functional compensation by Dpl.
The Immune System of Prno/o Mice. Prnd mRNA is transcribed in
the spleen (7), and we detected splenic Dpl protein (Fig. 2G),
suggesting a role for Dpl in lymphoid cells. However, immune
functions are normal in Prndneo/neo mice (10). PrPC is also
expressed in spleen (Fig. 2G) and was claimed to have functions
in immune cells (25), including T cell activation (26).
If Dpl and PrP have overlapping immunological functions,
Prno/o mice might exhibit immune defects. We, therefore,
analyzed the prevalence of subsets of immune cells in Prno/o
and littermate control mice (two 6- to 8-week-old mice for each
group). B cells, T cells, and monocytesmacrophages were
represented normally in peripheral blood and spleen (Fig. 2 A
and B). CD4 and CD8 T cell subsets in spleen and periph-
eral blood were indistinguishable from those of controls
(Fig. 2C). Spleen cell suspensions showed no abnormalities in
splenic CD21highCD23neg-low marginal-zone B cells and
CD21med/lowCD23high follicular B cells (Fig. 2D). There was no
Fig. 2. FACS analysis of immune cell subsets in Prno/o mice and wild-type littermates. Normal population of T cells (Thy1.2) (A), macrophagesmonocytes (CD11b)
(A and B), and B cells (B220) (B) in peripheral blood and spleen of wild-type and Prno/o mice, as indicated. (C) FACS analysis of peripheral blood and spleen revealed
no alteration in CD4 and CD8 T cell subsets in mutant mice. (D) Similar density of B220 splenic marginal-zone B cells (CD21high CD23neg-low) and B220 follicular
B cells (CD21med/low CD23high; circles). (E–F) Analysis of bone-marrow cells did not indicate alterations in the prevalence of AA4.1B220low immature B cells, AA4.1
B220high mature B cells, B220 AA4.1 hematopoietic progenitor cells, and Ter119 erythroblasts of Prno/o mice. Percentages of gated living cells are shown. (G)
Western blot analysis of Dpl and PrPC in spleen.
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detectable alteration in the prevalence of immature B cells,
hematopoietic progenitor cells, or erythroblasts in the bone
marrow of Prno/o mice (Fig. 2 E and F).
To test the functionality of the immune system as a whole, at
least two 6–8 week-old Prno/o and control mice were infected
with LCMV or VSV. Viability of cytotoxic CD8 T cell immune
responses was tested by immunizing wild-type, Prndneo/neo, and
Prno/o mice by i.v. injection of 200 pfu of LCMV. LCMV-specific
cytotoxic T lymphocytes were identified in blood by staining with
gp33–41:H2Dbtetramers 13 days later. Controls and mutant
mice yielded a similar high LCMV-specific responses (Fig. 3A).
The LCMV-binding Ab response was similar in controls and
mutant mice (Fig. 3B). The capability of mice to mount CD4
T helper-dependent humoral immune responses was tested in
the VSV-infection paradigm. On i.v. immunization of 2 106 pfu
of VSV, wild-type and Prno/o mice did not show any significant
difference in the production of neutralizing total Igs (Fig. 3C) or
IgG (Fig. 3D). Therefore, loss of PrP and Dpl does not impair
the efficacy of these antiviral responses.
Disruption of Dpl Abrogates Cerebellar Degeneration of ZH-II Mice. At
6 months of age, Dpl-overexpressing ZH-II mice develop
progressive tremor and unsteady gait associated with PC loss
(12). This phenotype is 100% penetrant at 13 months of age.
However, ZH-I mice show no ataxia or PC loss at up to at least
72 weeks (ref. 12; see Fig. 5). We, therefore, studied the
cerebellar morphology of Prno/o mice. Dpl was detectable by
Western blotting in ZH-II brains but not in wild-type brains,
whereas removal of both Prnd alleles from ZH-II mice abrogated
ectopic brain expression of Dpl (Fig. 4A). Similarly, PrP expres-
sion was absent in the brain of Prno/o mice (Fig. 4B). Testicular
Western blots failed to reveal any expression of PrPC and of Dpl
in testis of Prno/o mice (Fig. 4 A and B), whereas wild-type mice
exhibited strong signals for both proteins. The electrophoretic
mobility of testicular Dpl (35 kDa) was slightly slower than that
of brain Dpl (30 kDa) possibly because of differential glyco-
sylation.
Aging Prno/o mice were scored clinically, and none exhibited
tremor or unsteady gait (62 weeks; n  5). At 62 weeks, Prno/o
mice showed intact PC layers and normally sized cerebella (Fig.
5), whereas ZH-II mice exhibited significant PC loss (12). Glial
fibrillary acidic protein staining of the cerebellar cortex revealed
strong astrocytosis in ZH-II mice but not in Prno/o, wild-type, or
ZH-I mice (Fig. 5). These results prove that Dpl overexpression,
rather than loss of Prnp or of additional cis-acting elements,
causes ataxia and PC loss in ZH-II mice.
Discussion
The Prnp gene is conserved in mammals (27), and paralogues are
present in turtle (28), fish (29, 30), and amphibians (31),
suggesting an important function of PrPC. No natural Prnp null
alleles were described despite negative evolutionary pressure
(32). Mild phenotypes were found in Prnp knockout mice (23),
but no molecular explanations for these observed phenotypes
have come forward (18). Identifying the function of PrPC may be
crucial to understanding the basis for neurodegeneration in
prion diseases (33).
Dpl-deficient mice develop normally yet suffer from male
infertility (10). Structural similarities and overlapping expression
patterns in certain tissues suggest that Dpl may compensate for
the loss of PrPC, and vice versa. Yet, neurotoxicity related to
overexpression of Dpl can be counteracted by PrPC, suggesting
that Dpl and PrPC may feed antagonistically into a common
pathway.
We addressed the functional relationship between PrPC and
Dpl by sequentially deleting Prnp and Prnd in mice. These two
genes are separated by only 16 kb; hence, double-knockout mice
could not be generated by Mendelian crosses. We, therefore,
used TAMERE, which has been used to modify Hox gene
clusters (17). The generation of Prno/o mice confirms that
TAMERE is not restricted to specific loci and that it can be used
broadly for producing complex ‘‘designer chromosomes.’’
The low frequency of TAMERE in our experiments (0.2%
deletion events) contrasts with ref. 17 (10% deletion and dupli-
cation events). Recombination frequency can vary 1–10% (34).
There does not appear to be a clear-cut correlation between the
genomic distance of the loxP sites and the frequency of recom-
bination (M. Kmita and D. Duboule, personal communication).
For Prn, the distance between the two loxP sites was 17,534 bp,
whereas Hox-cluster deletions encompassed 0.5–22 kb.
Fig. 3. Susceptibility of control and Prno/o mice to LCMV and VSV. (A) To
assess CD8 T cell immune responses, control mice, Prndneo/neo, and Prno/o mice
were immunized by i.v. injection of 200 pfu of LCMV. LCMV-specific cytotoxic
T lymphocytes (CTL) were assessed in blood by using gp33–41:H2Db-tetramers
13 days later. Controls and mutants mice yielded similar high LCMV-specific
responses. (B) LCMV-neutralizing Ab responses were similar in control and
mutant mice. (C and D) On i.v. immunization of 2  106 pfu of VSV, controls
and Prno/o mice mounted a similarly strong production of neutralizing total Igs
(C) or IgG (D).
Fig. 4. Dpl and PrP protein levels in testes and brains of wild-type,
Prndneo/neo, ZH-I, ZH-II, and Prno/o mice. (A) Western blot analysis was per-
formed on tissue homogenates with rabbit anti-Dpl polyclonal Ab. Overex-
pression of Dpl in the brain of ZH-II mice is abrogated in Prno/o. (B) As expected,
Western blot analysis did not reveal expression of PrPC in brain and testis of
Prno/o mice. Detection was done by using anti-PrP ICSM18 Ab.











The normal development of Prno/o mice suggests that Dpl does
not transcomplement PrPC during brain development. Prno/o
males suffered from infertility similarly to Prndneo/neo mice,
indicating that removal of PrPC does not rescue sperm dysfunc-
tion. Although it is surprising in view of the structural homology
between PrPC and Dpl (35), this finding may be due to the lack
of functional overlap between PrPC and Dpl. Alternatively,
further unknown homologues, which may have retained a struc-
ture similar to PrPC and Dpl despite sequence diversification
(36), may provide redundancy.
Although PrPC and Dpl are expressed in lymphoid organs,
Prno/o mice had normal hematopoiesis and lymphopoiesis, and
they mounted normal cytotoxic and humoral immune responses
against LCMV and VSV. This finding is exciting in view of the
resiliency to immunization of certain C-proximal domains of
both proteins. Dpl may cross-tolerize against PrPC because PrPC
expression in lymphoid organs is extremely tolerogenic and the
C termini of PrPC and Dpl are structured similarly. Because
Prno/o mice appear to be fully immunocompetent, they may be
useful for generation of Abs to novel PrP epitopes.
Dpl is overexpressed in ZH-II brains by means of intergenic
splicing events that place Prnd under the control of the Prnp
promoter. ZH-II mice develop ataxia and PC degeneration.
Reintroduction of a single allele of Prnp abrogates degeneration.
Several lines of evidence suggested that overexpression of Dpl
was responsible for this neurodegenerative phenotype in the
brain of ZH-II mice. (i) Dpl is highly expressed in brain of ataxic
ZH-II and Ngsk mice but not in brains of ZH-I mice that never
become ataxic (16); (ii) the onset of ataxia correlates inversely
with Dpl levels in brains of PrPC-deficient mice (12); and (iii)
targeted expression of a Dpl transgene to PC induces ataxia in
Prnpo/o mice but not in Prnp/ mice (37).
Although the above data suggest a causal role for Dpl in
neurodegeneration of Prnpo/o mice, deletion of the Prnd locus in
neurodegeneration-prone ZH-II mice provides formal proof
that Prnd expression, rather than loss of PrP or other cis-acting
regions, causes the development of neurological syndromes and
PC degeneration.
Overexpression of N-terminally truncated PrPC transgenes
(PrP) causes degeneration of cerebellar granule-cell layers in
ZH-I Prnpo/o mice. However, reintroduction of PrPC prevents
disease (38). Because the truncation deprives PrPC of regions
that are absent also from Dpl, PrP and Dpl may cause disease
by means of similar mechanisms. The present results confirm
that Dpl and PrPC feed antagonistically into a common cere-
bellar pathway, possibly because they bind to a common receptor
(provisionally termed ‘‘LPrP’’ in ref. 39) or because they form
heteromultimers whose neurotoxicity depends on their PrPDpl
stoichiometry (18).
Conversion of PrPC to PrPSc may bring about a toxic
alteration of its normal function, which may be ultimately
responsible for prion pathology. The toxicity induced by Dpl
and PrP, as well as its specific suppression by PrPC, represents
the only possibility currently available for understanding the
function of PrPC in vivo. The Prno/o mice described here may
help to elucidate the structure–function relationships of PrPC
domains, which, in turn, may contribute to the understanding
of prion diseases.
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Fig. 5. Cerebellar histopathology of Prnp and Prnd mutant mice. (Top) Parasagittal sections of wild-type, ZH-I, ZH-II, and Prno/o mice stained with
hematoxylineosin. (Middle) Glial fibrillary acidic protein (GFAP) staining of cerebellar cortex with gliosis in ZH-II mice, but not in wild-type, ZH-I, or Prno/o mice.
(Bottom) Calbindin stains (specific for PC). Wild-type, ZH-I, and Prno/o mice show an intact PC layer, whereas ZH-II mice undergo extensive cell loss.
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